Abstract Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time,
exerting a significant impact on physical and mental health and leading to death. The …

Abstract Changes over 50 years of research on antipsychotics in schizophrenia have
occurred. A scientometric synthesis of such changes over time and a measure of …

The goal of this guideline is to improve the quality of care and treatment outcomes for
patients with schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental …

Abstract Treatment-resistant schizophrenia (TRS) will affect about one in three patients with
schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be …

Importance It has remained unclear whether there are clinically meaningful differences
between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Importance The effectiveness of antipsychotic polypharmacy in schizophrenia relapse
prevention is controversial, and use of multiple agents is generally believed to impair …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …

Introduction Antipsychotic medications are mainstays in the treatment of schizophrenia and
a range of other psychotic disorders. Sources of data Recent meta-analyses of antipsychotic …

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults
across different stages, phases, and symptom domains. Method: Guidelines were developed …